<DOC>
	<DOCNO>NCT00606775</DOCNO>
	<brief_summary>Purpose This cardiac dysfunction patient Duchenne muscular dystrophy associate minor cardiac damage indicate elevation plasma cardiac troponin I ( cTnI ) . The purpose study investigate whether administration Carvedilol suppress minor cardiac damage prevent deterioration cardiac function .</brief_summary>
	<brief_title>The Preventive Efficacy Carvedilol Cardiac Dysfunction Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>The life span patient Duchenne muscular dystrophy extend due development artificial respiratory device . According , ratio cardiac dysfunction cause death increase . This cardiac dysfunction associate minor cardiac damage indicate elevation plasma cardiac troponin I ( cTnI ) . Furthermore , detection rate cTnI plasma reveal correlated deterioration speed LV dysfunction assess serial echocardiography measurement . Accordingly , minor cardiac damage suppress , postulate progression cardiac dysfunction stop . In case ventricular arrhythmia tachycardia , find plasma cTnI become undetectable administration beta-blocker . Accordingly , investigate whether administration beta-blocker , carvedilol persistently suppress minor cardiac damage lead suppress deterioration LV function . Note study preventive study preserve moderate LV dysfunction intend beta-blocker treatment severe LV dysfunction . Because assume mechanism elevation cTnI different ; spontaneous preserve mild LV dysfunction patient LV wall stress severe LV dysfunction patient Duchenne muscular dystrophy .</detailed_description>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Male patient Duchenne muscular dystrophy require meet follow criterion : 1 . Aged ８ 45 year 2 . Positive plasma cardiac troponin I ( 0.06ng/mL ) least 4 blood measurement every 3 month . 3 . Left ventricular ejection fraction &gt; 30 % echocardiography assessment 4 . Written informed consent Patients follow condition exclude study : 1 . Left ventricular ejection fraction &lt; 30 % 2 . No plasma cTnI elevation 3. betablocker already administer without measurement plasma cTnI 4 . Contraindication treatment β blocker 5 . Any serious disease could potentially complicate management followup protocol</criteria>
	<gender>Male</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Adrenergic beta-Antagonists</keyword>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>Cardiomyopathies</keyword>
	<keyword>Troponin I</keyword>
</DOC>